Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Authors:
- Mazen NoureddinMNMazen Noureddin
- Emily TruongETEmily Truong
- Rebeca MayoRMRebeca Mayo
- Ibon Martínez-ArranzIMIbon Martínez-Arranz
- Itziar MincholéIMItziar Mincholé
- Jesus M. BanalesJesus M. Banales
- Marco ArreseMAMarco Arrese
- Kenneth CusiKCKenneth Cusi
- María Teresa Arias-LosteMAMaría Teresa Arias-Loste
- Radan BruhaRBRadan Bruha
- Manuel Romero-GómezMRManuel Romero-Gómez
- Paula IruzubietaPIPaula Iruzubieta
Open Access
- 24 July 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 79 (1) , 135-148
Abstract
Background: Early identification of those with NAFLD activity score ≥ 4 and significant fibrosis (≥F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a priority as these patients are at increased risk for disease progression and may benefit from therapies. We developed and validated a highly specific metabolomics-driven score to identify at-risk MASH. Methods: We included derivation (n = 790) and validation (n = 565) cohorts from international tertiary centers. Patients underwent laboratory assessment and liver biopsy for metabolic dysfunction-associated steatotic liver disease. Based on 12 lipids, body mass index, aspartate aminotransferase, and alanine aminotransferase, the MASEF score was developed to identify at-risk MASH and compared to the FibroScan-AST (FAST) score. We further compared the performance of a FIB-4 + MASEF algorithm to that of FIB-4 + liver stiffness measurements (LSM) by vibration-controlled transient elastography (VCTE). Results: The diagnostic performance of the MASEF score showed an area under the receiver-operating characteristic curve, sensitivity, specificity, and positive and negative predictive values of 0.76 (95% CI 0.72–0.79), 0.69, 0.74, 0.53, and 0.85 in the derivation cohort, and 0.79 (95% CI 0.75–0.83), 0.78, 0.65, 0.48, and 0.88 in the validation cohort, while FibroScan-AST performance in the validation cohort was 0.74 (95% CI 0.68–0.79; p = 0.064), 0.58, 0.79, 0.67, and 0.73, respectively. FIB-4+MASEF showed similar overall performance compared with FIB-4 + LSM by VCTE (p = 0.69) to identify at-risk MASH. Conclusion: MASEF is a promising diagnostic tool for the assessment of at-risk MASH. It could be used alternatively to LSM by VCTE in the algorithm that is currently recommended by several guidance publications.Keywords
This publication has 27 references indexed in Scilit:
- Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohortsHepatology Communications, 2018
- Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLDJournal of Hepatology, 2017
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohortHepatology, 2016
- Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD StatementEuropean Urology, 2015
- Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and ElaborationAnnals of Internal Medicine, 2015
- Valganciclovir for the Prevention of Complications of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Cell TransplantationAnnals of Internal Medicine, 2015
- Stable feature selection for biomarker discoveryComputational Biology and Chemistry, 2010
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological LesionsAmerican Journal of Gastroenterology, 1999